Stroke
📧 Sign up to get email alerts when something new happens for Stroke.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2015-02-03EMA Withdrawn: Clopidogrel Teva Pharma B.V. (clopidogrel (as hydrobromide)) — Teva Pharma B.V.
The EMA withdrew clopidogrel Teva Pharma B.V. (clopidogrel as hydrobromide) from marketing.
-
CLINICAL_TRIALS withdrawal · 2015-01-12Clinical Trial Update: RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke [Phase 2]
A Phase 2 randomized trial evaluating a neuroplasticity agent combined with constraint-induced therapy for severe arm paresis after stroke h…
-
CLINICAL_TRIALS withdrawal · 2014-12-12Clinical Trial Update: Anticoagulation in AF Ablation and Effects on Neurocognitive Function [Phase 4]
This Phase 4 trial investigating anticoagulation in atrial fibrillation patients undergoing ablation and its effects on neurocognitive funct…
-
CLINICAL_TRIALS withdrawal · 2014-12-08Clinical Trial Update: Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection [Phase 1]
A Phase 1 pilot trial comparing aspirin versus warfarin for cervicocephalic arterial dissection has been withdrawn.
-
EMA withdrawal · 2014-09-08EMA Withdrawn: Clopidogrel Qualimed (clopidogrel (as hydrochloride)) — Qualimed
EMA withdrew Clopidogrel Qualimed (clopidogrel hydrochloride) from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2014-08-20Clinical Trial Update: China Stroke Secondary Prevention Trial [NA]
The China Stroke Secondary Prevention Trial has been withdrawn from ClinicalTrials.gov.
-
CLINICAL_TRIALS withdrawal · 2014-08-13Clinical Trial Update: Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity [Phase 3]
A Phase 3 long-term study of onabotulinumtoxinA for adult upper limb spasticity has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-08-07Clinical Trial Update: Hybrid Approach to Unilateral vs. Bilateral Upper Limb Rehabilitation in Subacute and Chronic Stroke [NA]
The clinical trial comparing unilateral versus bilateral upper limb rehabilitation after subacute and chronic stroke has been withdrawn.
-
EMA withdrawal · 2014-05-12EMA Lapsed: Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride)) — Teva Pharma B.V.
EMA has lapsed the marketing authorization for Clopidogrel Teva Generics B.V. (clopidogrel as hydrochloride).
-
CLINICAL_TRIALS withdrawal · 2014-05-05Clinical Trial Update: Source of Hand Weakness After Stroke [Phase 2]
A Phase 2 clinical trial investigating the source of hand weakness after stroke has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-02-25Clinical Trial Update: Cognitive & Motor Training After Stroke For Everyday Walking Restoration [NA]
A clinical trial (NCT01160653) evaluating cognitive and motor training after stroke to improve everyday walking was withdrawn.
-
EMA withdrawal · 2013-12-12EMA Withdrawn: Clopidogrel ratiopharm (clopidogrel) — Archie Samuel s.r.o.
Withdrawn clopidogrel product (Clopidogrel ratiopharm) listed by EMA; therapeutic areas include peripheral vascular diseases, stroke, and my…
-
CLINICAL_TRIALS withdrawal · 2013-11-11Clinical Trial Update: IVIG in Acute Ischemic Stroke: A Pilot Study [Phase 1]
A Phase 1 pilot trial evaluating intravenous immunoglobulin (IVIG) for acute ischemic stroke was withdrawn, with status listed as withdrawn …
-
CLINICAL_TRIALS withdrawal · 2013-09-13Clinical Trial Update: Study for the Use of Alteplase in Patients Who Awaken With Stroke [Phase 1]
A Phase 1 clinical trial evaluating alteplase for patients who awaken with ischemic stroke was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-07-11Clinical Trial Update: Dynamic Splinting for Excessive Pronation Following CVA [NA]
A clinical trial evaluating dynamic splinting for pronation contracture after stroke has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-02-28Clinical Trial Update: The Clinical Trial Research of Stem Cell Transplantation Treats Cerebral [Phase 2]
A Phase 2 clinical trial investigating stem cell transplantation for stroke has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-21Clinical Trial Update: The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury [Phase 1]
A Phase 1 trial evaluating transcranial direct current stimulation for implicit motor learning in patients with traumatic brain injury or st…
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Hexal (clopidogrel) — Acino Pharma GmbH
Clopidogrel Hexal (clopidogrel) has been withdrawn from the market by Acino Pharma GmbH.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma GmbH (clopidogrel) — Acino Pharma GmbH
Clopidogrel product from Acino Pharma GmbH has been withdrawn from the market.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma (clopidogrel) — Acino Pharma GmbH
The EMA withdrew Clopidogrel Acino Pharma (clopidogrel) from use; linked to peripheral vascular diseases, stroke, and myocardial infarction …
-
CLINICAL_TRIALS withdrawal · 2012-06-19Clinical Trial Update: Escitalopram Treatment In Acute Stroke [Phase 4]
A Phase 4 trial evaluating escitalopram for acute stroke has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-06-15Clinical Trial Update: Comparative Evaluation of Stroke Triage Algorithms for Emergency Medical Dispatchers
A clinical trial evaluating stroke triage algorithms for emergency medical dispatchers has been withdrawn.
-
EMA withdrawal · 2011-10-26EMA Withdrawn: Clopidogrel Sandoz (clopidogrel) — Acino Pharma GmbH
The EMA indicates withdrawal of Clopidogrel Sandoz (clopidogrel) by Acino Pharma GmbH.
-
CLINICAL_TRIALS withdrawal · 2011-09-05Clinical Trial Update: REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients [Phase 2]
A Phase IIb trial evaluating NTx-265 (hCG and epoetin alfa) for acute ischemic stroke has been withdrawn.
-
EMA withdrawal · 2010-01-26EMA Withdrawn: Clopidogrel BMS (clopidogrel (as hydrogen sulfate)) — Bristol-Myers Squibb Pharma EEIG
The EMA information indicates that the clopidogrel BMS product (clopidogrel as hydrogen sulfate) has been withdrawn from the market.